OBrien Christopher Flint 4

4 · NEUROCRINE BIOSCIENCES INC · Filed Nov 6, 2017

Form 4

Period: 2017-11-02

Sr. VP & Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2017-11-02$8.66/sh+45,299$392,289→ 94,272 total
Sale
Common Stock
2017-11-02$69.71/sh−45,299$3,157,594→ 48,973 total
Exercise/Conversion
Common Stock
2017-11-02$8.65/sh+7,518$65,031→ 56,491 total
Sale
Common Stock
2017-11-02$69.71/sh−7,518$524,047→ 48,973 total
Exercise/Conversion
Non Qualified Stock Option
2017-11-02$8.66/sh+31,250$270,625→ 14,049 total
Exercise: $8.66Exp: 2022-01-12→ Common Stock (31,250 underlying)
Exercise/Conversion
Incentive Stock Option
2017-11-02$8.66/sh+14,049$121,664→ 0 total
Exercise: $8.66Exp: 2022-01-12→ Common Stock (14,049 underlying)
Exercise/Conversion
Non Qualified Stock Option
2017-11-02$8.65/sh+7,518$65,031→ 62,823 total
Exercise: $8.65Exp: 2023-01-10→ Common Stock (7,518 underlying)

Footnotes (4)

[F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
[F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $68.21 to $71.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]Option granted January 12, 2012 and vested monthly over four years.
[F4]Option granted January 10, 2013 and vested monthly over four years.

Documents

1 file